Characterization of the Adaptive and Innate Immune Response to Intravenous Oncolytic Reovirus (Dearing Type 3) During a Phase I Clinical Trial
Gene Therapy - United Kingdom
doi 10.1038/gt.2008.21
Full Text
Open PDFAbstract
Available in full text
Date
March 6, 2008
Authors
Publisher
Springer Science and Business Media LLC